A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer

Guihuan Qiu; Fei Wang; Xiaohong Xie; Ting Liu; Chen Zeng; Ziyao Chen; Maolin Zhou; Haiyi Deng; Yilin Yang; Xinqing Lin; Zhanhong Xie; Gengyun Sun; Chengzhi Zhou; Ming Liu

doi:10.1002/cam4.5843

Cancer Medicine (Jul 2023)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer

Guihuan Qiu,
Fei Wang,
Xiaohong Xie,
Ting Liu,
Chen Zeng,
Ziyao Chen,
Maolin Zhou,
Haiyi Deng,
Yilin Yang,
Xinqing Lin,
Zhanhong Xie,
Gengyun Sun,
Chengzhi Zhou,
Ming Liu

Affiliations

Guihuan Qiu: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Fei Wang: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Xiaohong Xie: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Ting Liu: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Chen Zeng: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Ziyao Chen: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Maolin Zhou: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Haiyi Deng: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Yilin Yang: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Xinqing Lin: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Zhanhong Xie: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Gengyun Sun: Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Anhui Medical University Hefei China
Chengzhi Zhou: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
Ming Liu: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

DOI: https://doi.org/10.1002/cam4.5843
Journal volume & issue: Vol. 12, no. 14
pp. 14881 – 14891

Abstract

Read online

Abstract Background The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC by January 2022. However, currently, there is limited real‐world data on ES‐SCLC patients received immunotherapy. Methods We retrospectively collected and analyzed the demographic and treatment data of ES‐SCLC patients at the First Affiliated Hospital of Guangzhou Medical University from January 2017 to January 2022. Survival and prognosis information was obtained through follow‐up. Results A total of 353 ES‐SCLC patients were included, of which 165 received immunotherapy combined with chemotherapy as the first‐line (FL) treatment (chemo‐immune group), and 188 received chemotherapy (chemotherapy group). The objective response rate (ORR) and disease control rate (DCR) of patients receiving immunotherapy as the FL treatment were better than the chemotherapy group (76.97% vs. 48.40%, p < 0.001, and 83.03% vs. 68.09%, p < 0.001). Moreover, the progression‐free survival (PFS) and overall survival (OS) of ES‐SCLC patients receiving immunotherapy as the FL treatment were better than the chemotherapy group (6.7 months vs. 5.1 months, p < 0.001, and 12.5 months vs. 11.2 months, p < 0.001). Furthermore, the OS of ES‐SCLC patients who received immunotherapy as second‐line treatment was better than that in the chemotherapy group (15.9 months vs. 12.9 months, p = 0.036). Conclusion ICIs combined with chemotherapy as the FL treatment could be beneficial to the ORR, DCR, PFS, and OS of ES‐SCLC patients. Furthermore, ES‐SCLC patients can benefit from ICIs in the second‐line treatment, even if they had not received ICIs in the FL treatment.

Published in Cancer Medicine

ISSN: 2045-7634 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/20457634

About the journal

Abstract

Keywords